{"nctId":"NCT02730299","briefTitle":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","startDateStruct":{"date":"2016-12-16","type":"ACTUAL"},"conditions":["Hematological Malignancies","Acute Lymphoblastic Leukemia (ALL)","Acute Myelogenous Leukemia (AML)","Chronic Myelogenous Leukemia (CML)","Myelodysplastic Syndrome (MDS)","Lymphoma","Acute Leukemia"],"count":125,"armGroups":[{"label":"NiCord® (omidubicel)","type":"EXPERIMENTAL","interventionNames":["Drug: NiCord® (omidubicel)"]},{"label":"Unmanipulated CBU(s)","type":"ACTIVE_COMPARATOR","interventionNames":["Other: Cord Blood Unit"]}],"interventions":[{"name":"NiCord® (omidubicel)","otherNames":[]},{"name":"Cord Blood Unit","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Applicable disease criteria\n* Patients must have one or two partially HLA-matched CBUs\n* Back-up stem cell source\n* Adequate Karnofsky/Lansky Performance score\n* Sufficient physiological reserves\n* Signed written informed consent\n\nExclusion Criteria:\n\n* HLA-matched donor able to donate\n* Prior allogeneic HSCT\n* Other active malignancy\n* Active or uncontrolled infection\n* Active/symptoms of central nervous system (CNS) disease\n* Pregnancy or lactation","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"65 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to Neutrophil Engraftment","description":"The time to engraftment of neutrophils \\>500/μl was defined as per Center for International Blood and Marrow Transplant Research (CIBMTR) standards, requiring donor chimerism for neutrophil engraftment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"First Grade 2/3 Bacterial or Invasive Fungal Infections by 100 Days Following Transplantation","description":"First Bacterial Infection Grades 2-3 or Invasive Fungal Infection by 100 Days following Transplantation for the Intent to Treat Population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Days Alive and Out of Hospital in the First 100 Days Post-transplantation","description":"Days alive and out of hospital in the first 100 Days post-transplantation for the Intent to Treat Population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.5","spread":null},{"groupId":"OG001","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Platelet Engraftment by 42 Days Post-transplantation","description":"Platelet engraftment defined as the first day of a minimum of three consecutive measurements on different days such that the patient has achieved a platelet count \\> 20 × 10\\^9/L with no platelet transfusions during the preceding seven days (counting day of engraftment as one of the preceding seven days) for the Intent to Treat Population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":47,"n":52},"commonTop":["Pyrexia","Gastrointestinal Toxicity","Mucosal Inflammation","Pain","Vomiting"]}}}